CellMade is developing a biochemical inflammatory biomarker pipeline for drug R&D and clinical diagnostics in diseases with inflammatory pathology. These include cancer, cardiovascular disease, Alzheimer’s and autoimmune diseases such as rheumatoid arthritis (RA).
Our cell-based biomarker discovery platform, CellInsight™ has been designed to faithfully replicate the in vivo situation, using human-derived primary cells in co-cultures, coupled to highly sensitive lipidomics bioanalysis technology. We enable research teams in pharmaceutical and biotechnology companies to discover and validate novel biomarker profiles that can be critical tools for effectively evaluating drug efficacy, using human data in the drug discovery phase. We also provide our technology for efficacy screening of novel small molecule or biological therapeutics in drug discovery, using the most relevant CellInsight™ cell model for the inflammatory pathway of interest.
Inflammatory biomarkers discovered using our platform have the potential to be used for clinical diagnostics, or as companion diagnostics to identify suitable treatments as part of a personalized medicine approach.
CellMade’s IP portfolio includes simple to complex lipid profiles that predict a drug’s effect on early TNF alpha receptor activation. These profiles constitute mechanistic biomarkers that are a critical research tool for identifying and validating new therapeutic targets, for evaluating the effects of potential new treatments in preclinical studies, and ultimately in personalized medicine.
CellMade’s biomarker IP is available for out-licensing to pharmaceutical and biotechnology companies. Contact us for more information.